KNBIF (Kane Biotech) Moat Score: 2/10 (As of Jun. 24, 2026)


What is Kane Biotech Moat Score?

Kane Biotech KNBIF +5.19% Moat Score is 2 as of Jun. 24, 2026. The stock has 6 warning signs investors should review. Among 1,405 Biotechnology companies, Kane Biotech ranks better than 58.15% on this metric.

Kane Biotech has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Kane Biotech has No Moat: Kane Biotech has very weak competitive advantages, with limited market share and brand strength. It lacks significant intellectual property or regulatory barriers, resulting in a transient competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kane Biotech might have No Moat - Very weak/transient advantages.

Kane Biotech  (OTCPK:KNBIF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kane Biotech Moat Score Related Terms

KNBIF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Kane Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kane Biotech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Kane Biotech (KNBIF) has a Moat Score of 2 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Kane Biotech ranks #588 out of 1405 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Kane Biotech's Moat Score too high?
Kane Biotech's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Kane Biotech's value of 2 is 0% at this industry median. Based on the distribution chart, Kane Biotech ranks #588 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint.
How does Kane Biotech's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #588 out of 1405 companies for Moat Score. This puts Kane Biotech in the upper half of its industry. The industry median Moat Score is 2.00. Kane Biotech's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Moat Score is 2 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.